Maternal and fetal hemodynamic effects induced by nitric oxide donors and plasma volume expansion in pregnancies with gestational hypertension complicated by intrauterine growth restriction with absent end-diastolic flow in the umbilical artery.
OBJECTIVE
To evaluate the effect of plasma volume expansion (PVE) and nitric oxide (NO) donors, in addition to antihypertensive therapy for gestational hypertensive pregnancies complicated by intrauterine growth restriction (IUGR) with absent end-diastolic flow (AEDF) in the umbilical artery (UA).


METHODS
This was a case-control study into which 32 gestational hypertensive pregnancies with IUGR and AEDF were enrolled. Sixteen of these were treated with antihypertensive drugs, NO donors and PVE (Group A), and 16, matched for maternal age, gestational age and fetal conditions, were treated with antihypertensive drugs only (Group B). All patients underwent fetal and uteroplacental assessment and maternal echocardiography to evaluate total vascular resistance (TVR) and cardiac output before and 5-14 days after initiation of treatment.


RESULTS
After 5-14 days of treatment, the maternal TVR in Group A fell from 2170 +/- 248 to 1377 +/- 110 dynes.s.cm(-5) (P < 0.01), and that in Group B fell from 2090 +/- 260 to 1824 +/- 126 dynes.s.cm(-5) (P < 0.01), with the reduction being greater in Group A than in Group B (P < 0.01). There was a significant increase in cardiac output in Group A after 5-14 days of treatment vs. baseline (6.19 +/- 0.77 vs. 4.32 +/- 0.66, P < 0.001), and, after treatment, cardiac output was significantly greater in Group A than it was in Group B (6.19 +/- 0.77 vs. 4.70 +/- 0.44, P < 0.001). Reappearance of end-diastolic flow in the UA occurred in 14/16 patients in Group A but in no patients in Group B (87.5% vs. 0%, P < 0.05). The interval between detection of UA-AEDF and delivery was 28 +/- 16 days in Group A and 11 +/- 6 days in Group B (P < 0.05).


CONCLUSIONS
Administration of NO donors and PVE in gestational hypertensive pregnancies affected by IUGR and UA-AEDF appears to improve both maternal and fetal hemodynamics, inducing prolongation of gestation.
D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D016022:Case-Control Studies; D004078:Dihydralazine / Q000008:administration & dosage / Q000627:therapeutic use; D015150:Echocardiography, Doppler / Q000379:methods; D005260:Female; D005317:Fetal Growth Retardation / Q000000981:diagnostic imaging*; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D046110:Hypertension, Pregnancy-Induced / Q000188:drug therapy*; D020030:Nitric Oxide Donors / Q000008:administration & dosage / Q000627:therapeutic use*; D021041:Placental Circulation / Q000187:drug effects / Q000502:physiology; D010953:Plasma Volume / Q000502:physiology; D011247:Pregnancy; D014469:Umbilical Arteries / Q000002:abnormalities / Q000000981:diagnostic imaging*
D000959:Antihypertensive Agents; D020030:Nitric Oxide Donors; D004078:Dihydralazine